Document issued by Global Marketing.
Content based on international published data.

NeuroAiD™
Reconnect

NeuroAiD™
Sustains Stroke Recovery

Moleac

This document provides scientific data and information exclusively meant for healthcare professionals.

NeuroAiD stimulates brain self-repair processes for stroke recovery

NeuroAiD up-regulates endogenous growth factors relevant in the neurovascular niche such as BDNF [1]

NeuroAiD promotes neurogenesis and neuroplasticity [1]



Increases number of mature neuronal cells

Epifluorescence microscopy of a double-labelling BrdU/NeuN (neuronal marker) cells after BrdU injection in mice with 6 week-treatment with NeuroAiD.

Control NeuroAiD™



Increases neurite outgrowth and synaptogenesis

Epifluorescence microscopy of DCX (neuronal precursor marker) protein expression in neuronal cells cultures at 14 days.

NeuroAiD protects against neuronal damage [2,3]

- Reduces the infarct volume by ~50% both in post-stroke and post-TBI rodents model.
- Increases cell survival.
- Activates ATP-dependent K^+ channels contributing to neuroprotection and ischemic preconditioning.

This document provides scientific data and information exclusively meant for healthcare professionals.

Persisting benefits in stroke

The CHIMES-E study

FUNCTIONAL INDEPENDENCE

Modified Ranking Scale	n	OR (95% CI)*	
mRS shift at 24 months	862	1.08 (0.85, 1.37)	
mRS dichotomy 0-1 vs. 2-6			
Month 6	878	1.49 (1.11, 2.01)	p=0.008
Month 12	877	1.41 (1.05, 1.90)	p=0.023
Month 18	870	1.36 (1.01, 1.83)	p=0.045
Month 24	862	1.29 (0.96, 1.74)	p=0.093



** Adjusted for age, sex, stroke onset to study treatment, baseline NIHSS and pre-stroke mRS.*

Patients recruited and initiated on a 3-month course of NeuroAiD vs Placebo within 72 hours of ischemic stroke onset [4] and followed up to 24 months. [5]

50% increase in odds of achieving independence at 6 months.

Benefits persisting over time.

Excellent safety profile at 24 months.

Suggests extending the treatment duration beyond 3 months. [5]

This document provides scientific data and information exclusively meant for healthcare professionals.

Benefits observed as early as 3 months

~65% increase in odds of achieving independence

- Among post-acute patients with established deficits [4]



Post-acute patients*, consistent with previous trials

Chen et al, Stroke 2013

- Similar effects size in patients with challenging prognosis (eg. older, more severe, delayed treatment) [6,7]

Improves motor recovery [8]

50% reduction in early vascular events
(recurrent stroke, acute coronary events or vascular death) [9]

NeuroAiD is safe and well-tolerated

Safety well established in ischemic stroke patients in the post-acute and chronic stages and up to 24 months follow up. [4,5,10]

This document provides scientific data and information exclusively meant for healthcare professionals.

Key facts about NeuroAiD in stroke recovery

Pharmacology

NeuroAiD amplifies self-repair processes of the brain

- ✓ Stimulates BDNF expression.
  - Promotes neurogenesis and maturation of new neuronal cells.
  - Increases neurite outgrowth and synaptogenesis.
- ✓ Activates neuroprotection and ischemic preconditioning (K-ATP channels opening).
- ✓ Increases cells survival.

Efficacy

NeuroAiD enhances recovery after stroke

- ✓ Increases chances of achieving functional independence at post-acute and chronic stages.
- ✓ Benefits increase at 6 months and persist over time.
- ✓ Improves motor recovery.

NeuroAiD prevents early vascular events and deaths after stroke.

Safety

NeuroAiD is safe and well-tolerated as an add-on treatment in neurological recovery.

Recommended use

- ✓ Ischemic Stroke, TBI and other neurological pathologies.
- ✓ 3-month course. Consider additional courses when appropriate*.
- ✓ Dosage: 4 capsules, 3 times a day.

**Based on medical judgment.*

This document provides scientific data and information exclusively meant for healthcare professionals.

References:

1. Heurteaux C, et al. Neuroprotective and neuroproliferative activities of NeuroAiD (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology 2010; 58:987-1001.
2. Quintard H, et al. MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after Traumatic Brain Injury in rats. Neuroscience 2014;277:72-86.
3. Moha Ou Maati H, et al. Activation of ATP sensitive potassium channels as an element of the neuroprotective effects of the traditional Chinese medicine MLC901 against oxygen glucose deprivation. Neuropharmacology 2012; 63:692-700.
4. Chen C, et al. Chinese Medicine Neuroaid Efficacy on Stroke Recovery – A double-blind, placebo-controlled, randomized study. Stroke 2013; 44: 2093-2100.
5. Venketasubramanian N, et al. CHInese Medicine NeuroAiD Efficacy on Stroke recovery – Extension Study (CHIMES-E): A multicenter study of long-term efficacy. Cerebrovascular Diseases 2015.
6. Navarro J, et al. Baseline characteristics and treatment response of patients from the Philippines in the CHIMES study. International Journal of Stroke 2014;9:102-105.
7. Chankrachang S, et al. Prognostic Factors and Treatment Effect in the CHIMES Study. Journal of Stroke and Cerebrovascular Diseases 2015;24(4):823-827.
8. Harandi AA, et al. Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial. Stroke Research and Treatment 2011; doi:10.4061/2011/721613.
9. Chen C, et al. Effects of MLC601 on early vascular events in patients after stroke: The CHIMES study. Stroke 2013b;44:3580-3583.
10. Young SHY, et al. Safety profile of MLC601 (NeuroAiD) in Acute Ischemic Stroke Patients: a Singaporean Substudy of the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery Study; Cerebrovascular Diseases 2010; 30: 1-6.

Note:

NeuroAiD™ is a trademark of Moleac. MLC601 and MLC901 are 2 different proprietary formulae which have been shown to be equivalent in pharmacology and are referred as NeuroAiD in this brochure.

For more information go to : www.moleac.com or Email : medical@moleac.com

Moleac Pte Ltd
11 Biopolis Way, Helios Building
#09-08, Singapore 138667
Tel: +65 6211 3710
Fax: +65 6478 9435

Moleac Europe SAS
92, rue de la Victoire,
75009 Paris, France
Tel: +33 14 878 42 61
Fax: +33 14 878 48 31

Moleac Poland (Rep. office)
AIP Business Link, 65 Mogilska Street
31-545 Cracow, Poland
Tel: +48 22 550 60 34
Moleac.poland@moleac.com

Moleac

MAR/DBNA1/280415/04

This document provides scientific data and information exclusively meant for healthcare professionals.